Efficacy of Alirocumab, Evolocumab, and Inclisiran in Patients with Hypercholesterolemia at Increased Cardiovascular Risk

<i>Background and Objectives:</i> Lowering low-density lipoprotein (LDL-C) levels is critical for preventing atherosclerotic cardiovascular disease, yet some patients fail to reach the LDL-C targets despite available intensive lipid-lowering therapies. This study assessed the effectiveness and safet...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Renata Rajtar-Salwa, Beata Bobrowska, Sylwia Socha, Artur Dziewierz, Zbigniew Siudak, Jakub Batko, Stanisław Bartuś, Agata Krawczyk-Ożóg
Format:	Artigo
Jezik:	Inglês
Izdano:	MDPI AG 2024-07-01
Serija:	Medicina
Teme:	alirocumab evolocumab inclisiran hypercholesterolemia proprotein convertase subtilisin/kexin type 9 inhibitors
Online dostop:	https://www.mdpi.com/1648-9144/60/7/1124
Oznake:	Označite Brez oznak, prvi označite!